Could a nasal spray fight Alzheimer's? early trial begins
NCT ID NCT07187141
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested a nasal spray called Protollin in 16 people with early Alzheimer's disease. The main goal was to see if it is safe and tolerable. The spray is designed to boost the immune system in the brain, possibly helping to clear away harmful proteins linked to Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Protollin (nasal spray)
- What this could lead to
- If safe and effective, this could point toward a new way to treat Alzheimer's by stimulating the immune system to clear harmful proteins from the brain.
- What could go wrong
- This is a very early, small Phase 1 trial focused only on safety, not on whether the drug works. Many promising early treatments fail in later, larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common supplement slow Alzheimer's decline?
- Could a simple beat help Alzheimer's patients walk better?
- Lifestyle makeover could slash Alzheimer's risk in genetically vulnerable seniors
- New study offers hope for lonely Alzheimer's caregivers
- New cognitive test aims to catch Alzheimer's earlier with help from memory nurses
- Can silkworm powder boost brain health in Alzheimer's?